Histogenics (HSGX) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Histogenics (HSGX) Misses Q2 EPS by 8c
August 12, 2015 6:30 AM EDT
- Continued Progress on NeoCart® Phase 3 Trial and 2015 Business Objectives -
- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT -
WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the quarter ended June 30, 2015.
"The second quarter was one of transition as we hired several new executives to drive the further development and commercialization of NeoCart," stated Adam Gridley, President and Chief... More
August 12, 2015 6:30 AM EDT
- Continued Progress on NeoCart® Phase 3 Trial and 2015 Business Objectives -
- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT -
WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the quarter ended June 30, 2015.
"The second quarter was one of transition as we hired several new executives to drive the further development and commercialization of NeoCart," stated Adam Gridley, President and Chief... More
